Stockscreener 앱 받기
93.93
0.50%
-0.47
시장 영업 전:
94.26
0.33
+0.35%
전일 마감가:
$94.40
열려 있는:
$94.97
하루 거래량:
6.85M
Relative Volume:
0.53
시가총액:
$163.61B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
26.17
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
-1.54%
1개월 성능:
+5.34%
6개월 성능:
-25.41%
1년 성능:
-29.69%
1일 변동 폭
$93.47
$94.97
1주일 범위
$92.99
$98.14
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Healthcare Stocks: J&J, UnitedHealth, Abbott Face Test on Sector’s 9% Earnings Drop - TechStock²
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty - The Motley Fool
Abbott stock holds steady as its diagnostics business anchors the outlook. - ad-hoc-news.de
Abbott (ABT) Stock Still Looks Cheap On Cash Flow And Earnings - simplywall.st
Richard Dean Dr McCormick of GA06 Makes Multiple Trades, Including Abbott Laboratories and Intercontinental Exchange - Investing.com Nigeria
A Senator Finally Asks the Question I've Been Asking: Where Did the Abbott Criminal Case Go? - Marler Blog
Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Abbott Laboratories stock holds steady as healthcare demand supports long-term growth - ad-hoc-news.de
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income - ChartMill
Schiff launches inquiry into DOJ's closure of probe into Abbott Labs over bacterial contamination at baby formula plant - CBS News
Abbott Laboratories stock stays supported by diversified health-care business - ad-hoc-news.de
The Company Accused of Poisoning Baby Formula Gave Trump $500,000. Then the Criminal Case Was Dropped. - Yahoo
Abbott Laboratories stock may move 4.5% on earnings release - Investing.com
ABBOTT LABORATORIES: TURNING BIG IDEAS INTO ACTIONABLE PLANS - McDermott Will & Schulte
Abbott Laboratories highlights diagnostics and medical devices as investors assess long-term growth - AD HOC NEWS
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus - Yahoo Finance
Abbott Laboratories balances diagnostics demand and investor expectations - Ad-hoc-news.de
Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut? - Insider Monkey
FreeStyle Libre 3 Sensor from Abbott Laboratoriesdiscreet glucose tracking for active diabetes pa - AD HOC NEWS
Is Abbott Laboratories (ABT) Undervalued After Its Glucose Monitoring Growth Narrative? - simplywall.st
Abbott (ABT) Has a Multi-Platform Device-and-Diagnostics Engine Bigger Than the Libre Narrative - AlphaStreet
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Evercore ISI Adjusts Abbott Laboratories Price Target to $112 From $120 - Moomoo
Abbott Laboratories (ABT) Stock Analysis: A Healthcare Giant with a 22.35% Upside Potential - DirectorsTalk Interviews
DOJ Closing Abbott Labs Case Spurs Wider Corporate Crime Retreat - Bloomberg Law News
Abbott Laboratories Stock (ABT) Opinions on Recent FDA Approvals and Product Launches - Quiver Quantitative
Abbott Labs must face lawsuit over PediaSure children's growth claims - MSN
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering - Seeking Alpha
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability - ChartMill
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)? - simplywall.st
DOJ ends investigation into infant formula company linked to deadly cronobacter outbreak - foodsafetynews.com
Abbott Laboratories (ABT) Shares Surge 3.5% -- What GF Score of 80 Tells Investors - GuruFocus
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula - Reuters
Trump Loaded Up on Abbott Laboratories Stock Before His DOJ Dropped Criminal Probe - Common Dreams
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File. - KFF Health News
Abbott Laboratories (NYSE: ABT) director receives 432 stock equivalent units as deferred fees - Stock Titan
Abbott Laboratories (ABT) director granted 416 stock equivalent units as board fees - Stock Titan
Abbott (ABT) director receives 363 stock equivalent units as board compensation - Stock Titan
Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees - Stock Titan
Form 4 Abbott Laboratories For: 1 July By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) director receives 347 stock equivalent units as board compensation - Stock Titan
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott (NYSE: ABT) EVP withholds 269 shares to satisfy tax obligations - Stock Titan
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value? - simplywall.st
Baird starts Abbott at Outperform, sees product pipeline driving growth - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.49%
자본화:
|
볼륨(24시간):